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Introduction
Psychiatric disorders constitute a rising global problem due to high prevalence, great disease burden and increased societal costs. 1 Anxiety disorders are amongst the most common, with a global worldwide prevalence of around 6·5%, 2 They often have their onset in childhood, 3 and can lead to significant disability, reduced quality of life and long-term medical and psychosocial adversity. 4 Treatment of anxiety disorders early in life is therefore imperative. Cognitive behaviour therapy (CBT) is considered the first-line treatment for paediatric anxiety disorders, 5 but only a fraction of those who need it have access to this treatment. 6 Multiple access barriers have been identified, such as geographical distances and limited healthcare resources, and internet-delivered cognitive behaviour therapy (ICBT) has been put forward as a way to potentially increase the availability of evidence-based psychological treatments in a cost-effective manner. 7 To date, six randomised controlled trials (RCT) have evaluated ICBT with limited online therapist support in school-aged children and adolescents with anxiety disorders, with promising results. [8] [9] [10] [11] [12] [13] However, before ICBT can be recommended for implementation in routine clinical care, more rigorous trials employing active control conditions that reduce the impact of potential confounders are needed. 14 The main aim of this study was to evaluate the clinical efficacy and costeffectiveness of a therapist-guided ICBT protocol for children with anxiety disorders (BiP Anxiety), 8 compared to an active control condition (internet-delivered Child-Directed Play; ICDP), which aimed to improve parent-child relationships and increase the child's self-esteem but did not directly target anxiety. It was hypothesized that ICBT would be more efficacious and cost-effective than ICDP.
Method

Study design
The current study was a single blind-, parallel assignment-, randomised-controlled trial comparing 12 weeks of either therapist-supported and parent-assisted ICBT or ICDP. Participants initially randomised to ICDP were offered the option to cross-over to ICBT after the primary end point (post treatment). All participants were naturalistically followed-up three months after ICBT. The study was conducted at a single site, a clinical research unit at the child and adolescent mental health services (CAMHS) in Stockholm, Sweden. This trial also collected long-term follow-up data in a stepped-care design, where non-responders were offered regular face-to-face CBT, which will be presented in a separate paper. The 
Participants
Participants were recruited nationally through newspaper advertisements and through referrals from CAMHS or primary care centres in Sweden. Inclusion criteria were (a) a principal diagnosis of separation anxiety disorder (SEP), generalized anxiety disorder (GAD), specific phobia (SP), social anxiety disorder (SAD) or panic disorder (PD) of at least moderate severity, b) 8-12 years of age, (c) ability to read and write in Swedish, (d) daily access to the internet, (e) a parent or caregiver who could participate in treatment, and (f) if on psychotropic medication, a stable dose for at least six weeks prior to assessment. Exclusion criteria were (a) a diagnosis of autism spectrum disorder, bipolar disorder, psychosis or severe eating disorder (b) current risk of suicide, (c) on-going substance dependence, and (d) completed CBT (>4 sessions of exposure treatment) within the last six months. Caregivers provided written consent to their child's participation in the study.
Randomisation and masking
Participants were randomly assigned to either ICBT or ICDP at a 1:1 ratio. Block sizes randomly varying between four and six and were generated using a computer random number generator (www.sealedenvelope.com). An independent researcher was responsible for the generated sequence and the allocation of participants to the two conditions. The allocation was concealed for members of the research group by opaque sealed envelopes. The study-coordinators (MJ and TW) were responsible for enrolment of participants and assigned participants to clinicians. Participants were informed that they would either be allocated to ICBT or a novel online intervention that had not been previously tested (ICDP). Clinicians conducting post-treatment assessments were blinded to the participant's allocation.
To measure blinding integrity, all assessors guessed each participant's treatment allocation and recorded whether the participating families had inadvertently revealed their group allocation. 15 As per protocol, blinding was broken at post treatment (primary endpoint). The naturalistic three-month follow-up assessments were thus unblinded.
Procedures
All participants were briefly screened via telephone to assess basic inclusion/exclusion criteria. Eligible participants were then scheduled for a face-to-face interview where inclusion/exclusion criteria were further assessed. Assessors conducted face-to-face interviews with participants at post-treatment and three-month follow-up. The ten clinical psychologists involved in the trial conducted all assessments and provided therapist support to participants randomised to both ICBT and ICDP. All psychologists were trained on the principles of ICBT and had weekly supervision. To increase inter-rater reliability on the primary outcome measure, all assessors underwent two days of training. After the training, assessors' ratings had to match those of an expert rater on at least two out of three pre-recorded assessments. The active comparator, ICDP, is directed to the parent only, and is based on a commonly used parentdirected intervention for children with conduct problems, which is intended to strengthen the parentchild relationship. 16 Parents are instructed to spend approximately 20 minutes, 3-4 times per week, playing with their child in a non-directive and praising manner and report back as homework assignments. ICDP was designed to control for therapist attention, for monitoring of symptoms, and for engaging participants in behaviour change (i.e., acquiring and practicing new skills), analogue with core features in ICBT. See Supplemental Table 1 for an overview of the ICDP modules.
Interventions
Outcomes
The primary outcome measure was the blind-rated Clinician Severity Rating (CSR) derived from the Anxiety Disorder Interview Schedule for DSM-IV: parent and child versions (ADIS-C/P) 17 . A CSRrating of ≥4 corresponds to meeting the diagnostic criteria for the principal diagnosis according to the ADIS-C/P.
Secondary outcomes were clinician-assessed, blind-rated global functioning measured with the Children's Global Assessment Scale (CGAS) 18 and improvement of global functioning measured with the Clinical Global Impression Scale -Improvement (CGI-I). 19 The CGI-I ranges from 1 = "Very much improved" to 7 = "Very much worse". Secondary outcome measures also included parent-and childrated anxiety and depression symptoms measured with the Revised Children's Anxiety and Depression
Scale (RCADS), 20, 21 everyday functioning measured with the Education, Work and Social Adjustment Scale (EWSAS), 22 and quality of life measured with KIDSCREEN-10. 23 
RCADS includes anxiety (RCADS-TAS) and major depressive disorder (MDDS) subscales. Only the RCADS-TAS was used in
the secondary outcome analyses. The MDDS was used to measure depressive symptoms at pre-treatment only.
Child-and parent reported data were collected through a secure online platform, and clinician-reported data were mainly collected manually on case report forms. See Supplemental Table 2 for detailed information about the timing of measures throughout the study.
Treatment expectancy/credibility was assessed at week 3, after at least one module was completed and families had had a chance to familiarise themselves with the treatment; participants were asked whether they thought that the treatment would be helpful in improving their child's wellbeing (yes/no).
Adherence (i.e., treatment compliance) was measured by recording how many modules were completed at the end of treatment. Engagement was measured by asking clinicians whether the participant actively and regularly worked with the exercises presented in the treatment programme (yes/no). Satisfaction was measured post treatment; participants were asked whether they were satisfied with the intervention (yes/no). Therapist time was measured as total time spent supporting the participants throughout the 12-week treatment period (time spent online and on the telephone with both child and parent). Additional measures were parental psychiatric symptoms measured with Hospital Anxiety and Depression scale (HADS) 24 at pre-treatment, and self-reported adverse events at post-treatment. Measures of technology acceptance and specific phobia will be reported separately in additional papers.
Costs associated with healthcare consumption (e.g., physician-and psychologist appointments), supportive resources (e.g. study help), medication, dietary supplements, the child's absence from school, parents' absence from work and productivity losses when in school or at work were measured with the parent-rated Trimbos/iMTA questionnaire for patients with a psychiatric disorder (TiC-P) 25 at pre-and post treatment. The costs of ICBT and ICDP were estimated using individual per participant therapist times and online platform maintenance costs (i.e., IT support, server costs and software updates).
Statistical analysis
Power analysis was based on the BiP Anxiety programme showing a between-group effect size (Cohen's d) of 1·66 when compared to a waitlist condition 8 and aimed to detect a medium effect (d=0·5) when compared to an active control condition. A sample size of N=128 (N=64 in each condition) was calculated to be sufficient based on 80% power with an alpha set at 0·05 (two-tailed).
Linear mixed models (LMM) were used to analyse differences on all continuous primary-and secondary measures between conditions from pre-to post treatment. Piecewise LMM were used for within-group analysis where follow-up data were included in the analysis with one knot at post treatment. Weekly measures were included in the models when available. Unblinded follow-up data were not used for the primary analysis (only pre-to post treatment data were included). Estimates for follow-up, as visually presented in Figure 2 , were based on within-group analysis. All available data (N=131) were used and no cases were excluded in the analysis. LMM were created by sequentially adding (a) random intercept, (b) random effect of time, (c) diagonal covariance type for random effects, and/or, (d) unstructured covariance structure for measurements. See Supplemental Table 3 for a description of chosen random effects and covariance structures for all outcome measures. Chi-square tests of model fit were used to evaluate and compare models and the model with the best log likelihood value was chosen before adding condition as a covariate. Effect size (Cohen's d) was based on estimated means derived from the LMM together with the observed pooled standard deviation. 26 Between-group effect size was based on differences in estimated means at post treatment together with the observed pooled between-group standard deviation at post treatment. Within-group effect size was based on differences in estimated means within a group combined with the observed pooled within-group standard deviation.
Cost data were analysed from a societal perspective, including the direct costs of the two experimental interventions, healthcare costs, and other societal costs. Individual participant resource-use frequencies at pre-and post-treatment time-points were multiplied with their respective unit costs. For a detailed description of cost estimates see Supplemental Table 4 . Costs were converted from Swedish krona (SEK) to Euro (€) according to the 2016 conversion rates. The full three-month period between pre-and post-treatment was estimated using linear interpolation, since TIC-P retrospectively covers a period of one month. Missing data for costs were, due to non-normally distributed data, handled with a nonparametric model for imputation based on random forest estimation. 27 KIDSCREEN-10 scores were converted to quality-adjusted life years (QALYs) using validated mapping algorithms. 28 Total costs, remission status, and QALYs were, due to the skewed nature of cost data, resampled using nonparametric bootstrapping with 5000 repetitions, and presented as mean costs with CI, mean cost differences between ICBT and ICDP, and incremental cost-effectiveness ratios (ICER; the ratio of costand effect differences between the interventions, indicating the incremental additional costs, or costsavings, for one additional QALY or participant in remission). To test the robustness of the results, sensitivity analyses were carried out by calculating the probability of cost-effectiveness within different willingness-to-pay scenarios (i.e., cost-effectiveness acceptability curve), and by increasing the cost of ICBT with 50%. Costs were not discounted, as the time frame of the study was less than one year.
Statistical significance was set at p<0·05 and 95% CI were used. The Wald method was used to determine confidence interval for numbers needed to treat (NNT). 29 Treatment response and remission were defined a priori as at least "Much improved" (<3) on the CGI-I, and as no longer meeting the criteria for the principal anxiety disorder (CSR<4 on the primary outcome measure), respectively.
Normal probability plots, residual plots, and Cook's distance were used to check assumptions for parametric tests. Independent t-tests were used to analyse patterns of missing data at post treatment and follow-up. Independent t-tests, Chi-square tests and Fischer's exact tests were used when comparing the treatment groups. Inter-rater reliability for the primary outcome measure was analysed using intraclass correlation coefficient (ICC). Twenty percent of pre-treatment assessments were randomly selected and re-assessed by an assessor blinded to the original assessment. Figure 1 and for a summary of baseline demographic and clinical data, see Table 1 . The median travel distance to our clinic was nearly 16 km (IQR 9·4 to 25·5).
Ten participants (8%) dropped-out from the study during treatment and did not provide post-treatment data. These participants had significantly higher parent-reported child anxiety symptoms (t=2·021, p=0·048), lower parent-reported child quality of life (t=2·269, p=0·027) and a higher number of comorbid diagnoses (t=2·678, p=0·009) at pre-treatment.
Insert Figure 1 and Table 1 approximately here (figure legend at the end of the manuscript)
The inter-rater reliability for the primary outcome measure, CSR, for all anxiety disorders, was good (ICC 0·724, 95% CI 0·56 to 0·83). See Table 2 for a detailed summary of statistics on all primary-and secondary outcome measures. Participants in both conditions improved significantly from pre-to posttreatment on the primary outcome measure (within-group effect size for ICBT: d=1·22, 95% CI 0·78 to 1·65; for ICDP: d=0·72, 95% CI 0·44 to 1·00). However, participants allocated to ICBT improved significantly more than those allocated to ICDP (estimated mean difference 0·79, 95% CI 0·42 to 1·16; p=0·002; Figure 2 , left panel). The estimated between-group effect size at post-treatment was d=0·77, 95% CI 0·40 to 1·15). This was also true for clinician-rated functional impairment, CGAS (estimated mean difference 3·96, 95% CI 1·14 to 6·78; p=0·027; d=0·51, 95% CI 0·14 to 0·88), and parent-rated child anxiety symptoms, RCADS-TAS-P (estimated mean difference 4·43, 95% CI 0·21 to 9·07, p<0·0001, d=0·35, 95% CI 0·02 to 0·72). ICBT participants continued to improve significantly from post-treatment to three-month follow up (estimated mean difference 0·64, 95% CI 0·42 to 0·87; p<0·0001). See Supplemental Table 5 for the within-group effects on all primary-and secondary outcomes for the ICBT treatment condition and Supplemental Table 6 for between-and within group effects based on observed data.
Insert Table 2 approximately here Based on available data, 51% (n=30) of participants in ICBT were classified as responders (CGI-I<3)
at post-treatment, compared to 16% (n=10) in ICDP (odds ratio 5·28, 95% CI 2·57 to 12·33, p<0·0001).
Additionally, 48% (n=29) of participants in ICBT no longer fulfilled diagnostic criteria for their principal anxiety diagnosis (CSR<4) at post treatment compared to 15% (n=9) in ICDP (odds ratio 5·41, 95% CI 2·26 to 12·90, p<0·0001). Numbers needed to treat (NNT) for ICBT to gain one additional participant in remission (i.e., no longer meeting the criteria for the principal anxiety disorder) were three (95% CI 2·85 to 3·15). Seventy percent (n=40) of participants in ICBT no longer met the criteria for their principal anxiety disorder at follow-up. See Supplemental Table 7 for a summary of response and remission data.
Fifty-seven participants crossed over to ICBT after completed ICDP (primary end-point), and six of these no longer fulfilled diagnostic criteria for their principal anxiety disorder before starting ICBT treatment. Intent-to-treat analysis show that participants improved significantly on the primary outcome measure, CSR, from immediately before to after ICBT (estimated mean difference 1·73, 95% CI 0·83 to 1·27, p<0·0001) and continued to improve further three months after ICBT (estimated mean difference 0·41, 95% CI 0·17 to 0·64, p=0·001; Figure 2 , right panel and Supplemental Table 8 ).
Based on available data and only those who fulfilled diagnostic criteria for their principal anxiety disorder before crossing over to ICBT (n=46), 52% (n=24) were in remission after ICBT, and 60%
(n=28) were in remission three months after ICBT. The mean number of completed ICBT modules were
M=6·47 (SD=3·46).
Insert Figure 2 approximately here (figure legend at the end of the manuscript)
Treatment condition was inadvertently revealed to blind assessors in 12% of cases (n=12 in ICBT and n=2 in ICDP). Post-hoc analyses excluding these participants confirmed the superiority of ICBT over ICDP (estimated mean difference 0·53, 95% CI 0·12 to 0·87; p=0·010; Supplemental Table 9 ), though the estimated between-group effect size at post-treatment was smaller (d=0·49, 95% CI 0·12 to 0·87).
The proportions of participants classified as responders and in remission at post-treatment were similar to those of the main analysis (see Supplemental Table 10 for a summary of response and remission data in this subgroup).
Data on treatment credibility (week 3), adherence, engagement and satisfaction, together with therapist support time are presented in Table 3 . ICBT was rated as significantly more credible than ICDP (x 2 9·60, p=0·002) three weeks into treatment. However, post-hoc analyses showed that treatment credibility was not significantly associated with treatment response, remission, adherence or engagement in treatment, or with improvement on the primary outcome measure (Supplemental Tables   11-12 and Supplemental Figure 2 ). The number of completed modules was similar across the two groups. For example, 92% (n=55) in the ICBT, and 80% (n=47) in the ICDP groups completed at least four modules, meaning they had started to actively work with the key components of the treatment.
Clinicians rated their participants as being equally engaged in both treatments. Clinicians spent more time supporting participants in the ICBT than in the ICDP groups. Families randomised to ICBT had higher satisfaction ratings at post-treatment.
Insert Table 3 approximately here
Cost-effectiveness analyses showed that the total societal costs were almost €500 lower in the ICBT condition compared to ICDP at post treatment (mean difference €-493·05, 95% CI -508·92 to -477·17).
Reduced healthcare costs were the largest component of the total cost difference (mean difference €348·89, 95% CI 337·39 to 360·38; Supplemental Figure 3 ). For a summary of resource use see Supplemental Table 13 . ICBT was associated with cost savings in all cost categories except for therapist time, where costs were on average €83.03 higher, where the cost of ICBT was on average €158·89 (95% CI 140·50 to 177·28), and the cost of ICDP €75·69 (95% CI 68·58 to 82·79). The incremental cost-effectiveness ratio (ICER) regarding total costs and remission was €-1436·81 (95% CI -1493·36 to -1380·26), indicating cost savings and higher probability of remission in ICBT compared to ICDP. Only minimal differences regarding QALYs were observed (mean difference of 0·02), due to which the calculation of an ICER value was not meaningful. Figure 3 depicts the corresponding costeffectiveness planes, i.e., the probabilistic distributions of cost and effect differences between the two interventions with values in the south-east quadrant indicating that ICBT is cost saving and more effective than ICDP. Overall, the probability of ICBT being cost effective was approximately 80% in a scenario where the willingness to pay more for the additional effect of ICBT would be €0, and approximately 100% at a willingness to pay €5000. See Figure 4 for the cost-effectiveness acceptability curve displaying the probability of ICBT of being cost-effective over ICDP given different willingnessto-pay scenarios. Sensitivity analyses showed that increasing the cost of ICBT with 50% decreased the cost saving effect of ICBT over ICDP only marginally to €-473·53 (95% CI -491·47 to -455·59).
Insert Figure 3 and 4 approximately here (figure legend at the end of the manuscript)
No severe adverse events (AE) were reported in either condition. The number of self-reported AE did not differ significantly between treatment conditions (x 2 0·07, p=0·786). See Table 4 for a detailed overview of reported AE in each treatment condition.
Discussion
This is the largest RCT to evaluate the efficacy of therapist-guided ICBT for paediatric anxiety disorders compared to an active control condition, and the first to include a health economic evaluation. A 12-week ICBT programme with limited online therapist support was more effective than an internetdelivered control intervention controlling for e.g., mode of delivery, therapist contact, and general behaviour change. This was true for clinician-rated symptom severity and functional impairment, remission rates, and parent-rated child anxiety. At post-treatment, 48% (n=29) of participants randomised to ICBT no longer fulfilled their principal diagnosis, compared to 15% (n=9) in ICDP.
Treatment gains were maintained for at least 3 months after the end of treatment, at which point 70% (n=40) of participants randomised to ICBT no longer met the criteria for their principal anxiety disorder.
Overall, these results regarding remission are comparable to previous waitlist-controlled trials of ICBT for paediatric anxiety disorders, 8, 11 and even face-to-face CBT trials for anxiety disorders. 5 Participants who crossed over to ICBT after the control treatment, also improved robustly on primary and secondary outcome measures. A majority of participants were satisfied with the treatment despite minimal contact with a therapist. No serious AE were reported. ICBT was also more cost-effective than ICDP, resulting in an average societal cost saving of €493 per participant. The main cost saving factor was the reduced use of healthcare in the ICBT group. Overall, the probability of ICBT being cost effective was high, even in scenarios where the willingness to pay more for ICBT would be zero. Overall, the results indicate that ICBT has potential to greatly increase access to evidence-based treatment for children with anxiety disorders in a cost-effective way.
Interestingly, ICBT was cost-effective compared to ICDP regarding remission rates but not QALYs.
The same observation was made in another trial of ICBT for adolescents with obsessive-compulsive disorder. 30 The changes in QALYs are based on child-reported quality of life, which did not improve in either the ICBT or the ICDP conditions. As it is highly unlikely that clinical improvements are not associated with improvements in quality of life, one possible explanation for this could be that available measures of quality of life may lack validity or sensitivity to change in children and adolescents with anxiety disorders.
This represents the largest RCT of ICBT for paediatric anxiety disorders to date and the first to be sufficiently powered to detect a superiority effect over an active control intervention. The inclusion of a truly active control condition helped reduce biases related to therapist support, symptom monitoring, homework assignments and behaviour change. Other strengths included the use and careful verification of the blinding procedures (true double blind trials are not possible in psychological interventions) and minimal data loss. Despite our efforts to present the active control condition as credible and meaningful, it was still rated as being less credible at week 3, which may have affected the expectations for improvement. However, credibility at week 3 did not seem related to either adherence with the treatment (number of completed modules), therapist-rated engagement with the therapy or, crucially, treatment outcomes; participants improved more with ICBT than with ICDP, regardless of whether they thought the treatment was credible or not. Some families inadvertently revealed their group allocation to the blind rater; post-hoc analyses revealed that excluding these participants did not change the overall conclusions of our study but it did reduce the magnitude of the effect sizes. Another potential limitation of the study is that the results may not generalise to the entire population of patients with anxiety disorders because the majority of participants were self-referred and their families highly educated.
Thus, despite the fact that many participants had multiple psychiatric comorbidities and a history of previous contact with CAMHS, participants in this trial may have been less complex and particularly motivated to engage in psychological treatment, compared to patients typically seen in regular CAMHS services. Furthermore, participants with missing data were more severely ill at baseline (i.e., higher
anxiety, lower quality of life, higher number of comorbid diagnosis), thus potentially limiting the generalizability of our findings to mild to moderately ill children. Also, there was a higher percentage of participants with SAD in ICDP compared to ICBT, which could have affected outcome since evidence suggest that SAD is associated with poorer treatment outcome in generic CBT. 31 Future research should focus on a better understanding of which participants benefit from ICBT and which do not. Post-hoc sub-analyses of e.g., severity and diagnosis as potential predictors of treatment outcome are planned for a secondary paper deriving from this dataset. Another limitation of the study is that the long-term effects of ICBT are unknown. Future studies with longer controlled follow-ups would be needed to address this question but there are few reasons to believe that ICBT should be different from traditional face-to-face CBT, which has a reasonably well-established durability.
ICBT should not be seen as a substitute for traditional face-to-face CBT but instead as an alternative 
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